Free Trial
LON:DNL

Diurnal Group (DNL) Share Price, News & Analysis

Today's Range
N/A
50-Day Range
27.30
27.30
52-Week Range
N/A
Volume
145,283 shs
Average Volume
483,617 shs
Market Capitalization
£46.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
DNL stock logo

About Diurnal Group Stock (LON:DNL)

Diurnal Group plc operates as a specialty pharma company worldwide. The company develops hormone therapeutics for the treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. The company offers an oral formulation of hydrocortisone granules in capsules for the treatment of pediatric adrenal insufficiency. It also develops Chronocort, which completed Phase II clinical trials targeting congenital adrenal hyperplasia and adrenal insufficiency. The company's early-stage pipeline products comprise Ditest, a native oral testosterone product, which has completed phase I clinical trial for the treatment of classical hypogonadism; siRNA, a short interfering RNA oligonucleotide therapy for patients suffering from adrenocorticotropin-dependent Cushing's syndrome; and T3 modified, a modified-release preparation of T3 (triiodothyronine) hormone for patients suffering from hypothyroidism. Diurnal Group plc was incorporated in 2015 and is headquartered in Cardiff, the United Kingdom.

DNL Stock News Headlines

Anyone can do this, rich and poor alike
I’ve been a financial analyst for almost three decades, but I don’t think I’ve ever seen anything quite like this before.
Da Nang Port Logistics JSC DNL
D&L Industries Inc
D&L Industries Inc (DNL)
D&L Industries Inc.
Form 8.3 - Diurnal Group plc
Anyone can do this, rich and poor alike
I’ve been a financial analyst for almost three decades, but I don’t think I’ve ever seen anything quite like this before.
Diurnal Group plc (DNL.L)
AIQ boosted by deal to supply NFT marketplace in Hong Kong
Diurnal drops after losses nearly double and it seeks funding
Diurnal nosedives on need for further funding
Diurnal dips as bosses give investor presentation
See More Headlines
Receive DNL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Diurnal Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
9/15/2020
Today
7/14/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
33
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£4.68 million
Book Value
GBX 12.70 per share

Miscellaneous

Free Float
N/A
Market Cap
£46.33 million
Optionable
Not Optionable
Beta
N/A
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Mr. Richard Edward Bungay A.C.A. (Age 53)
    ACA, B.Sc., BSc, Interim CEO, CFO, Company Sec. & Director
    Comp: $338k
  • Prof. Richard Ross
    Chief Scientific Officer & Exec. Director
  • Mr. Stewart Jones
    Operations Director
  • Mr. John Porter MBBS
    Ph.D., Chief Medical Officer
  • Mr. David Bevan (Age 55)
    Chief Bus. Officer

DNL Stock Analysis - Frequently Asked Questions

How were Diurnal Group's earnings last quarter?

Diurnal Group plc (LON:DNL) announced its quarterly earnings results on Tuesday, September, 15th. The company reported ($4.30) EPS for the quarter, topping analysts' consensus estimates of ($6.70) by $2.40.

How do I buy shares of Diurnal Group?

Shares of DNL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Diurnal Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Diurnal Group investors own include Allena Pharmaceuticals (ALNA), Abercrombie & Fitch (ANF), Ampliphi Biosciences (APHB), Cerecor (CERC), Revolution Lighting Technologies (RVLT), Spero Therapeutics (SPRO) and SRC Energy (SRCI).

This page (LON:DNL) was last updated on 7/14/2024 by MarketBeat.com Staff

From Our Partners